Credit Suisse Ag Exelixis, Inc. Put Options Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2020 Feb 12, 2021	BUY	$18.39 - $24.8 $2.33 Million - $3.14 Million	126,600 Added 120.69%	231,500 $4.65 Million
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $4.02 Million - $5.24 Million	-194,600 Reduced 64.97%	104,900 $2.57 Million
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $3.37 Million - $4.41 Million	-178,000 Reduced 37.28%	299,500 $6.4 Million
Q4 2018 Feb 13, 2019	BUY	$13.65 - $21.8 $6.31 Million - $10.1 Million	462,200 Added 3020.92%	477,500 $9.39 Million
Q3 2018 Nov 13, 2018	BUY	$15.87 - $22.4 $242,811 - $342,720	15,300 New	15,300 $271,000

460

246M

1.7M

1.02M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.07B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.